Kyowa Kirin (4151) Q3 2026 earnings summary

Executive summary

• 9M 2026 revenue rose 10.2% YoY to ¥384.9bn; core operating profit increased 46.8% to ¥97.0bn and profit rose 58.5% to ¥51.7bn.

• Growth was led by global strategic products and technology out-licensing; FX supported reported revenue by ¥19.8bn and core operating profit by ¥8.5bn.

• FY 2026 forecasts remained unchanged at revenue of ¥520.0bn, core operating profit of ¥130.0bn and profit of ¥75.0bn.

Financial highlights

• Gross profit increased to ¥288.4bn from ¥259.4bn; core operating profit rose to ¥97.0bn from ¥66.1bn on higher gross profit and lower R&D costs despite higher SG&A.

• Profit attributable to owners rose to ¥51.7bn from ¥32.6bn; profit before tax was ¥64.7bn versus ¥47.9bn.

• Profit included ¥20.2bn in rocatinlimab trial-closing costs and ¥5.0bn in related impairment losses; other impacts included ¥9.4bn in early-retirement costs and a ¥4.3bn established-medicines JV divestment gain.

• Other expenses increased to ¥30.9bn from ¥14.7bn, including contract-loss and impairment charges.

Outlook and guidance

• FY 2026 forecast: revenue ¥520.0bn (+4.7%), core operating profit ¥130.0bn (+18.4%), profit before tax ¥95.0bn (+8.9%) and profit ¥75.0bn (+11.9%); forecasts unchanged from May 7.

• 9M progress against the revised FY plan was 74% for revenue, 75% for core operating profit and 69% for profit; favorable FX may support results above plan, but guidance was unchanged.

• Libmeldy/Lenmeldy revenue grew 65.6% in 9M; outlook targets 30–40% CAGR over the next three years, supported by newborn screening and geographic expansion.